SAGE – Lightwave Study

This is a placebo-controlled study to evaluate the effects of SAGE-718 in participants with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease. The primary objective of the LIGHTWAVE study is to determine if the cognitive enhancements observed during the two-week LUMINARY dosing period will be sustained over a longer duration. The study will specifically evaluate the effectiveness of the drug using the Digit Symbol Substitution test, a brief cognitive assessment that is highly responsive to changes in cognition and is believed to provide the most accurate reflection of daily cognitive abilities in patients.

To be eligible for this study, a potential participant must:

Be between the ages of 50 and 80
Have noticed a change in your memory
Have a family member or loved one who can be available as a study partner during the study
Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease – This is one of our more mild studies, so no diagnosis needed – as long as the patient has noticed significant concerns with their memory

"*" indicates required fields

Step 1 of 3

Submit your interest to our team of specialists

Attention: Make sure to check that you fit the eligibility requirements.

First Name*

Last Name*

Email*

Phone Number*

To be eligible for this study, a potential participant must:

Be between the ages of 50 and 80
Have noticed a change in your memory
Have a family member or loved one who can be available as a study partner during the study
Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease – This is one of our mild studies, so no diagnosis is needed – as long as the patient has noticed significant concerns with their memory